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median age 65 yrs (range 23-78), male 12 pts, adenocarcinoma 7 pts, 
second-line erlotinib 10 pts, non-smokers 5 pts. Response assessment 
with clinical and/or conventional radiological methods showed 1 partial 
response (PR), 10 progression (PD), 2 stable disease (SD). Three pts 
were too early for response evaluation in this analysis. Overall disease 
control was 23%. All patients were evaluated with FDG-PET before 
erlotinib: mean maximum SUV (SUV-max) and SUV tumor/liver ratio 
was 9 (range 3,5-15) and 5 respectively. Six patients were assessable 
for response with FDG-PET that showed 1 PR, 2 SD and 3 PD. One 
patient with SD on FDG-PET had progression on CT-scan whereas 1 
pt with PD on FDG-PET had SD on CT-scan. As today the follow-up is 
too short to establish the prognostic value of FDG-PET (SUV and SUV 
ratio) in this subset of patients. Accrual is still ongoing and mature 
results will be presented at the XII world conference on lung cancer
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Evaluation of pulmonary tumors with PET/CT
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Background: F18-FDG PET/CT provides morphologic and metabolic 
information for diagnosis of malignant disease; however, increased glu-
cose uptake is not exclusive of cancer. We analyzed PET/CT capacity 
to study pulmonary tumors in Chilean population. 
Methods: 204 patients with solitary pulmonary tumors were prospec-
tively included in the study, 91 males, mean age 63.2 years (27-96). 
Exams were performed in a PET-CT Scanner Siemens Biograph 6. We 
studied the group with biopsy and/or follow up longer than 6 months, 
153 of the 204 fulﬁlled this requirements. 66 patients had nodules of 
less than 30 mm and 87 had masses between 31 and 120 mm. Based on 
radiological appearance and metabolic activity in PET/CT, lesions were 
classiﬁed in malignant (112), benign (30) and indeterminate (11).
Results: Malignancy was demonstrated in 106 of 112 lesions catego-
rized as malignant by PET/CT (94.6%); 6 false positive results were 
due to 4 infectious/inﬂammatory lesions and 2 benign carcinoid tumors. 
In the group considered as benign, 3 malignant lesions were demon-
strated by biopsy (10%, 2 metastasis of colorrectal cancer, 1 of thyroid 
cancer). In the indeterminate lesions group, 4 of 11 resulted malignant 
(36.3%, 2 lung cancer, 1 metastasis of kidney cancer and 1 of colic 
cancer). Median SUV Max was 10.5 (1.8-35.9) in the malignant group, 
1.0 (0.3-15.3) in the benign group, and 2.0 g/ml (0.7-5.3) in the indeter-
minate group. Difference on SUV of malignant and benign lesions was 
signiﬁcant. 
Positive predictive value (PPV) for malignancy in the malignant group 
was 94.6%. Malignant lesions were found in the 36.3% of the indeter-
minated group and in the 10% of the benign group. 
Conclusion: F18-FDG PET/CT is a reliable method for the study of 
pulmonary lesions, with a 94.6% positive predictive value for malig-
nancy and 90% of negative predictive value. In the indeterminated 
cases histological study is necessary a (33.6% of malignancy).
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Background: Staging procedures before surgical treatment of non-
small cell lung cancer (NSCLC) usually consist of chest CT scan, 
upper abdomen CT scan or abdomen ultrasound examination, and brain 
CT scan in selected individuals. The clinical suspicion of mediastinal 
lymph nodes involvement (N2 disease) is the indication for mediasti-
noscopy. The aim of the present study was to assess whether preopera-
tive Cyfra 21-1 or CEA serum measurement could help to predict the 
extension of NSCLC before surgery.
Methods: 49 patients (pts), 38 men, 11 women, median age 65 (42-81) 
years referred to the Department of Thoracic Surgery entered this study. 
Mediastinoscopy was performed in 14 pts, lymph node metastases 
were found in 5 pts (further treated with neoadjuvant chemotherapy). 
Primary surgical treatment was performed in 44 pts. Pathologic stage 
of disease was Ia-IIb in 37 pts and IIIa-IV in 7 pts. Cyfra 21-1 and CEA 
were measured with Elecsys Roche in sera collected before any surgi-
cal procedure. 
Results: Cyfra 21-1 values exceeding 3.3 ng/ml were found in 9/37 
pts with stage Ia-IIb and 8/12 pts with stage IIIa-IV (p=0.03). Median 
Cyfra 21-1 value was 1.93 (0.7-7.6) ng/ml in the pts with Ia-IIb stage 
of disease and 4.6 (1.0-14.5) ng/ml in others (p=0.04). 
Median CEA value was 2.59 (0.87-30.9) ng/ml in the pts with stage 
Ia-IIb and 3.17 (0.76-144.2) ng/ml in other pts (nonsigniﬁcant). Median 
CEA value was 13.8 (0.76-144.2) ng/ml in the group of pts with posi-
tive result of mediastinoscopy and 2.6 (1.0-4.81) ng/ml in those with 
negative mediastinoscopy (p=0.0001). 
Conclusion: Serum Cyfra 21-1 elevation before surgery of NSCLC 
may indicate higher pathologic stage of disease, elevated serum CEA is 
possibly predictive for N2 disease, found on mediastinoscopy. 
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Background: Fluorodeoxyglucose-Positron Emission Tomography/
Computed Tomography (FDG-PET/CT) is useful for the diagnosis of 
lung cancer. Accurate diagnosis of pulmonary nodule and lymph node 
metastasis contribute to the decision of treatment. 
Materials and Methods: 324 patients with suspected lung cancer 
was performed FDG-PET/CT Ninety-one tumors of 89 patients 70 
male, 19 female, mean age; 67.7years) were diagnosed histologically 
at Tokushima University Hospital from December 2005 to November 
2006. Standardized uptake value max (SUVmax) was used for evalu-
ation of FDG uptake at early phase and delay phase, and Retention 
Index (RI) was calculated in (SUVmax at delay phase- SUVmax at 
early phase) / SUVmax at early phase X 100 (%). We retrospectively 
